MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
15.95
-1.03 (-6.07%)
At close: Mar 28, 2025, 4:00 PM
15.84
-0.11 (-0.69%)
After-hours: Mar 28, 2025, 5:52 PM EDT

Company Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally.

It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.

MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd.
MediWound logo
Country Israel
Founded 2000
IPO Date Mar 20, 2014
Industry Biotechnology
Sector Healthcare
Employees 111
CEO Ofer Gonen

Contact Details

Address:
42 Hayarkon Street
Yavne, 8122745
Israel
Phone 972 7 797 14100
Website mediwound.com

Stock Details

Ticker Symbol MDWD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001593984
CUSIP Number M68830104
ISIN Number IL0011316309
SIC Code 2833

Key Executives

Name Position
Ofer Gonen B.Sc. Chief Executive Officer
Hani Luxenburg Chief Financial Officer
Dr. Shmulik Hess Ph.D. Chief Operating Officer and Chief Commercial Officer
Yaron Meyer Adv. Executive Vice President, General Counsel and Corporate Secretary
Dr. Ety Klinger MBA, Ph.D. Chief Research and Development Officer
Dr. Lior Rosenberg M.D. Co-Founder
Dr. Liron Gal Executive Director of Manufacturing Science and Technology
Barry J. Wolfenson Executive Vice President of Strategy and Corporate Development
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 424B3 Prospectus
Mar 27, 2025 EFFECT Notice of Effectiveness
Mar 19, 2025 F-3 Filing
Mar 19, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 19, 2025 20-F Annual and transition report of foreign private issuers
Mar 19, 2025 6-K Report of foreign issuer
Feb 12, 2025 6-K Report of foreign issuer
Feb 11, 2025 SCHEDULE 13G/A Filing
Jan 8, 2025 6-K Report of foreign issuer
Dec 19, 2024 6-K Report of foreign issuer